The Alzheimer’s drugs approved in recent years are administered through IV infusions, not pharmacy bottles.
Treatment is difficult, requiring monthly hospital visits, repeated brain scans and enough money or insurance coverage to absorb costs.
However, an ordinary amino acid has shown early promise in paving a new path forward. Additionally, it is already consumed by millions of people every day.
Everyday amino acid enters
The compound is arginine, an amino acid your body uses to build proteins. It is sold cheaply at any drugstore and found in everyday foods like chicken, nuts, and seeds.
Kanako Fujii and Professor Yoshitaka Nagai of Kindai University spent years observing the effects of the amino acid on protein clumps that affect the Alzheimer’s brain.
The answer was found within both flies and mice.
Slowing the formation of plaques
Amyloid-beta, or Aβ, is the protein at the heart of Alzheimer’s.
In a healthy brain, individual Aβ molecules drift around without much trouble. But once things start to go wrong, they stick to each other.
First, they clump into small toxic clusters, then into the dense amyloid plaques that show up under the microscope as the disease’s signature.
Arginine is thought to act as a chemical chaperone. In doing so, it may nestle up to a misbehaving protein and help it stay properly folded, prohibiting clumping.
The broader concept was established years ago in a foundational paper on protein conformational diseases.
In a test tube, the team poured arginine onto a notoriously sticky version of Aβ called Aβ42 and watched the aggregation slow.
The more arginine they added, the fewer clumps formed. This produced a clean, dose-dependent effect.
Moving beyond the lab dish
Lab dishes are easy to understand, but living animals are not. Because of this, the team began to observe two well-established Alzheimer’s models.
The first was a fruit fly engineered to produce a particularly aggressive form of human Aβ42, carrying a mutation that makes the protein especially prone to clumping.
For the second, they used a mouse line called AppNL-G-F, which carries three different familial Alzheimer’s mutations stacked on top of each other.
In both, animals drank arginine in their water for weeks. Flies proved to lived longer. Additionally, the mice did much better, offering new and important insight.
Less damage, improved performance
Brains from arginine-treated AppNL-G-F mice carried fewer of the dense plaques that mark advanced disease.
Levels of insoluble Aβ42 – the form that sticks together hardest and resists clearance – dropped as well.
Treated animals also acted differently. Untreated AppNL-G-F mice tend to flunk standard memory and behavior tasks.
Also, the ones on arginine performed measurably better in those same tests. A reduction in plaques on a microscope slide is one thing.
A mouse acting more like a healthy mouse is something else entirely. That’s where a treatment starts to show promise for human subjects.
Calmer brain immune cells
Plaques aren’t the only problem in Alzheimer’s. Resident immune cells called microglia react to amyloid buildup by pumping out inflammatory signals.
Over time, that neuroinflammation can damage neurons on its own, as detailed in a published review of the field.
In the arginine-treated mice, genes that drive brain inflammation were less active – suggesting the chemical signals microglia use to call in reinforcements were quieter.
Less amyloid and quieter immune responses equate to better behavior. These were three readouts moving in the right direction all at once.
A pre-approved drug
Arginine isn’t a mystery molecule. It’s already used clinically in Japan for unrelated conditions, has a long human safety record, and crosses the blood-brain barrier without much fuss.
Most Alzheimer’s drug candidates die in early human trials over toxicity or absorption problems.
Fortunately, arginine has cleared those hurdles already. Repurposing it for Alzheimer’s would skip years of preliminary safety testing and cost a fraction of what the antibody therapies now on the market run.
“Given its excellent safety profile and low cost, arginine could be rapidly translated to clinical trials for Alzheimer’s and potentially other related disorders,” said Nagai.
Before human trials are conducted
All of this happened in flies and mice carrying inherited Alzheimer’s , a setup that doesn’t fully represent all Alzheimer’s cases.
Whether these results translate to that more common form of the disease remains to be seen.
The doses used in the animals were also optimized for research and will need to be calibrated before any human trial can begin.
Cheaper path for treatment
Until this study, no one had shown that oral arginine could provide so much relief.
It was unknown to reduce amyloid plaques, lower insoluble Aβ42, calm brain inflammation, and rescue behavior in a mouse model carrying multiple familial Alzheimer’s mutations.
What the work does is provide clinicians an option already cleared for human use, ready for proper trials at a fraction of the cost of the antibody class.
The next disease-modifying treatment for Alzheimer’s may not come from a biotech lab at all. It may come from a bottle that’s been sitting in pharmacies for decades.
The study is published in the journal Neurochemistry International.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.
—–